Nothing Special   »   [go: up one dir, main page]

Keller et al., 2010 - Google Patents

Innate signaling regulates cross‐priming at the level of DC licensing and not antigen presentation

Keller et al., 2010

View PDF @Full View
Document ID
6407738816124560410
Author
Keller S
Schwarz K
Manolova V
von Allmen C
Kinzler M
Bauer M
Muntwiler S
Saudan P
Bachmann M
Publication year
Publication venue
European journal of immunology

External Links

Snippet

Innate stimuli, such as TLR ligands, are known to greatly facilitate cross‐priming. Currently it is unclear whether innate stimuli enhance cross‐priming at the level of cross‐presentation or at the level of T‐cell priming. In this study, we addressed this question by measuring cross …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Kleijmeer et al. Antigen loading of MHC class I molecules in the endocytic tract
Diebold Determination of T‐cell fate by dendritic cells
Lefrançois et al. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells
Chiang et al. Differential uptake and cross‐presentation of soluble and necrotic cell antigen by human DC subsets
Ludewig et al. Dendritic cells efficiently induce protective antiviral immunity
Ruedl et al. Cross‐presentation of virus‐like particles by skin‐derived CD8–dendritic cells: a dispensable role for TAP
Hao et al. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T‐lymphocyte responses and antitumour immunity
Sˇkoberne et al. The apoptotic-cell receptor CR3, but not αvβ5, is a regulator of human dendritic-cell immunostimulatory function
van der Vlist et al. Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4+ T cells but are incapable of cross‐presentation
Shi et al. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens
Leifert et al. Targeting plasmid‐encoded proteins to the antigen presentation pathways
Deauvieau et al. Human natural killer cells promote cross‐presentation of tumor cell‐derived antigens by dendritic cells
Keller et al. Innate signaling regulates cross‐priming at the level of DC licensing and not antigen presentation
Sartorius et al. Antigen delivery by filamentous bacteriophage fd displaying an anti‐DEC‐205 single‐chain variable fragment confers adjuvanticity by triggering a TLR 9‐mediated immune response
Xu et al. Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response
Aleyas et al. Impaired cross‐presentation of CD 8α+ CD 11c+ dendritic cells by J apanese encephalitis virus in a TLR 2/M y D 88 signal pathway‐dependent manner
Jiang et al. Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells
Eken et al. Ethanol inhibits antigen presentation by dendritic cells
Bahl et al. Analysis of apoptosis of memory T cells and dendritic cells during the early stages of viral infection or exposure to toll-like receptor agonists
Rahnefeld et al. Antigen‐presentation capacity of dendritic cells is impaired in ongoing enterovirus myocarditis
Ritchie et al. B‐Lymphocytes Activated by CD40 Ligand Induce an Antigen‐Specific Anti‐Tumour Immune Response by Direct and Indirect Activation of CD8+ T‐cells
González et al. Melanoma cell lysate induces CCR 7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells
Rock et al. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.
Liu et al. TAP peptide transporter-independent presentation of heat-killed Sendai virus antigen on MHC class I molecules by splenic antigen-presenting cells.
Taborska et al. SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors